Clinical trial NCT01518283: Study of Weekly Cabazitaxel for Advanced Prostate Cancer
Official title: Phase II Study of Weekly Cabazitaxel for Advanced Prostate Cancer in "Unfit" Hormone-Refractory Patients Previously Treated With Docetaxel
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hormone Refractory Prostate Cancer
Keywords: Weekly cabazitaxel.
Advanced Hormone-refractory prostate Cancer.
Unfit patients.
Lead sponsor: Spanish Oncology Genito-Urinary Group
Sponsor class: OTHER
First posted: 2012-01-25
Enrollment: 74
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multicenter open label non randomized phase II clinical trial of Weekly Cabazitaxel for Advanced Prostate Cancer in Hormone-Refractory Patients Previously Treated with Docetaxel.

The purpose of this study is to evaluate the activity of the weekly administration of cabazitaxel as time to progression by PSA at week 12.

Detailed description: The efficacy of three-weekly cabazitaxel is accompanied by an appreciable rate of serious side effects and toxic deaths. The toxicity rates observed, including grade III-IV neutropenia, febrile neutropenia and diarrhea, could be an obstacle to the use and management of a drug that, on the other hand, has demonstrated great activity. In the treatment of patients with prostate cancer, who have a larger number of morbidities than patients with breast cancer, we assume the risk that in the transition from clinical trial to clinical practice the drug will not be used much because of the risk of side effects, cost, the discomfort derived from the routine use of G-CSF and the lack of patient compliance with this type of regimens.

Rates of neuropathy, nail and conjunctive toxicity with this new taxane are not relevant, which suggests that weekly administration will not produce relevant toxicity problems. Weekly administration of other taxanes improved hematologic tolerance along with a better therapeutic range in some cases, increasing the dose intensity and activity without increasing the associated toxicity.

Phase I study has been reported studying weekly administration of cabazitaxel, recommended dose is 10 mg/m2, administered on days 1, 8, 15 and 22 every 5 weeks in a 1-hour infusion, being diarrhea the dose-limiting toxicity observed in this study.

Given the pharmacokinetic characteristics of this taxane and its activity and toxicity profile, cabazitaxel might be a good candidate for studying in a weekly administration regimen in patients with prostate cancer with a greater risk of toxicity associated with treatment every 3 weeks, such as patients who have received previous pelvic radiation therapy that affects more than 25% of the bone marrow reserve, patients over 75 years with a worse performance status (ECOG 2) or who have already experienced important hematologic toxicity in the previous treatment with docetaxel.

Eligibility criteria: Inclusion Criteria:

1. Patients who have given written informed consent.
2. Age ≥ 18 years.
3. ECOG 0-2.
4. Patients with a histologic or cytologic diagnosis of advanced prostate cancer (any Gleason grade).
5. Previous and ongoing castration by orchiectomy or LHRH agonists. Antiandrogen must be discontinued prior to study start.
6. Disease progression, clinically or radiologically documented, during or after treatment with docetaxel, with a minimum cumulative dose of 225 mg/m2.
7. "Unfit" patients defined as patients who satisfy at least one of the following criteria:

   * ECOG 2
   * Dose reduction due to febrile neutropenia during the previous treatment with docetaxel
   * Radiation therapy affecting more than 25% of bone marrow reserve
8. Documented metastatic disease and progressing after docetaxel treatment. Progression criteria is considered any of the following three or more than one at once:

   * Progressive elevation of PSA measured in three successive determinations one week difference between them at least;
   * Should be considered progression of measurable disease by RECIST criteria;
   * Bone progression as evidenced by the appearance of two or more new lesions on bone scan.
9. Patients who have received a maximum of one prior chemotherapy for metastatic disease.
10. Prior anticancer therapy should have been interrupted 28 days before the start of study treatment (the patient may have continued treatment with prednisone 5 mg bid.
11. Adequate blood, liver and kidney function:

    * Hemoglobin \> 9.0 g/dl
    * ANC \> 1.5 x 10\*9/L
    * Platelets \> 100 x 10\*9/L
    * AST/SGOT and ALT/SGPT \< 2.5 x ULN
    * Bilirubin \< 1.0 x ULN
    * Creatinine \<1.5 mg/dL x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance \<60 mL/min should be excluded (see Annex 7 for formula)
12. Adequate baseline cardiac function (LVEF ≥ 50%).
13. Life expectancy ≥ 12 weeks.
14. Patients must agree to use an effective contraceptive method during treatment with the study drug and up to 1 month after ending the treatment.

Exclusion Criteria:

1. Patients who received radiation therapy that exceeded 40% of the bone marrow reserve or that ended within the last 3 weeks prior to inclusion.
2. If being treated with radiation therapy, should be completed before the three weeks prior to initiation of treatment research.
3. Previous treatment with two or more chemotherapy regimens for metastatic disease. A new line of treatment is also when a patient receives again docetaxel after clinical, radiological or PSA progression to a prior regimen with docetaxel.
4. Previous treatment with chemotherapy or surgery in the last 4 weeks.
5. Peripheral neuropathy or stomatitis ≥ 2 (National Cancer Institute Common Terminology Criteria - NCI CTCAE vs. 4.03).
6. Any other type of cancer in the last 5 years, except for basal cell skin carcinoma.
7. Cerebral or leptomeningeal metastasis.
8. Myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass, congestive heart failure (NYHA class III or IV), stroke or transitory ischemic episodes.
9. Patients who present any severe or uncontrolled medical condition (including uncontrolled diabetes mellitus) or any other condition that may affect the patient's participation and study compliance.
10. Previous treatment with cabazitaxel.
11. Known hypersensitivity (≥ grade 3)to cabazitaxel, polysorbate 80, prednisone or prednisolone, or docetaxel or paclitaxel.
12. Known history of active infection that requires systemic antibiotic or antifungal treatment.
13. Patients who are receiving or expect to receive treatment with strong inhibitors or strong inducers of cytochrome CYP450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments) (see Annexes 5 and 6).
14. Patients being treated with any investigational product.

Primary outcomes:
measure: Time to progression by PSA at week 12, according to the PCCTWG II criteria.
timeFrame: 12 weeks
Secondary outcomes:
measure: time to PSA progression
timeFrame: Patients will be followed until PSA progression, an expected average of 6 months
measure: biochemical response rate
timeFrame: Patients will be followed until end of treatment, an expected average of 6 months
measure: Objective response rate
timeFrame: Patients will be followed until end of treatment, an expected average of 6 months
measure: Overall survival
timeFrame: Patients will be followed until death, an expected average of 18 months
measure: Evaluate the safety and tolerability profile of cabazitaxel.
timeFrame: 6 months (during treatment)
measure: Pain response
timeFrame: Until end of treatment, an expected average of 6 months
measure: Correlation between presence-absence of baseline pain with overall survival, time to progression and PSA response rate.
timeFrame: Until death, an expected average of 18 months
measure: Correlation of the Charlson co-morbidity index and ADL/IADL dependency indexes with survival and toxicity
timeFrame: Until death, an expected average of 18 months
measure: Assessment and quantification of Circulating Tumour Cells and level correlation between the beginning of treatment and their variation through treatment with time to progression and overall survival
timeFrame: Until death, an expected average of 18 months
Other outcomes:
Locations:
city: Santiago de Compostela
country: Spain
facility: Complejo Hospitalario Universitario de Santiago
state: A Coruña
city: L'Hospitalet de Llobregat
country: Spain
facility: Institut Català D'Oncologia L'Hospitalet (Ico)
state: Barcelona
city: Manresa
country: Spain
facility: Hospital de Sant Joan de Déu
state: Barcelona
city: Alcorcón
country: Spain
facility: Hospital Universitario Fundación Alcorcón
state: Madrid
city: Barcelona
country: Spain
facility: Hospital Clinic I Provincial de Barcelona
city: Madrid
country: Spain
facility: Hospital General Universitario Gregorio Marañón
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Ourense
country: Spain
facility: Complejo Hospitalario de Ourense
city: Sevilla
country: Spain
facility: Hospital Virgen Del Rocío
city: Sevilla
country: Spain
facility: Hospital Nuestra Señora de Valme
city: Valencia
country: Spain
facility: Fundación Instituto Valenciano de Oncología
city: Valencia
country: Spain
facility: Consorcio Hospital General Universitario de Valencia
Study officials:
affiliation: FUNDACIÓN INSTITUTO VALENCIANO DE ONCOLOGÍA, Servicio de Oncología Médica, Profesor Beltrán Báguena, 11, 8 y 19, Valencia, 46009
name: Miguel A Climent, MD
role: PRINCIPAL_INVESTIGATOR
References: